These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30736155)

  • 1. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
    Hendrix LN; Hamilton DA; Kyprianou N
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Begemann D; Anastos H; Kyprianou N
    Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
    Li P; Yang R; Gao WQ
    Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving resistance specificity in prostate cancer.
    Wadhwa B; Dumbre R
    Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.
    Grant CM; Kyprianou N
    Transl Androl Urol; 2013 Sep; 2(3):202-211. PubMed ID: 25346895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
    Livas L; Hasani S; Kyprianou N
    Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
    Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-mesenchymal transition in prostate cancer: an overview.
    Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
    Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target.
    Castellón EA; Indo S; Contreras HR
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoskeleton targeting value in prostate cancer treatment.
    Martin SK; Kamelgarn M; Kyprianou N
    Am J Clin Exp Urol; 2014; 2(1):15-26. PubMed ID: 25374905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
    Dicken H; Hensley PJ; Kyprianou N
    Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis.
    Matuszak EA; Kyprianou N
    Expert Rev Endocrinol Metab; 2011 May; 6(3):469-482. PubMed ID: 23667383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.